American National Bank & Trust Has $11.46 Million Holdings in Laboratory Co. of America Holdings (NYSE:LH)

American National Bank & Trust lifted its holdings in Laboratory Co. of America Holdings (NYSE:LH - Free Report) by 2.2% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 49,251 shares of the medical research company's stock after purchasing an additional 1,082 shares during the period. Laboratory Co. of America makes up 1.3% of American National Bank & Trust's holdings, making the stock its 27th biggest holding. American National Bank & Trust owned approximately 0.06% of Laboratory Co. of America worth $11,463,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the business. Graney & King LLC acquired a new stake in Laboratory Co. of America during the 4th quarter worth $26,000. Geneos Wealth Management Inc. raised its stake in Laboratory Co. of America by 309.8% during the 4th quarter. Geneos Wealth Management Inc. now owns 168 shares of the medical research company's stock worth $39,000 after acquiring an additional 127 shares in the last quarter. Human Investing LLC acquired a new stake in Laboratory Co. of America during the 4th quarter worth $39,000. Heck Capital Advisors LLC acquired a new stake in Laboratory Co. of America during the 4th quarter worth $44,000. Finally, SBI Securities Co. Ltd. acquired a new stake in Laboratory Co. of America during the 4th quarter worth $52,000. Institutional investors and hedge funds own 95.94% of the company's stock.

Wall Street Analyst Weigh In

LH has been the topic of several analyst reports. Robert W. Baird lifted their target price on shares of Laboratory Co. of America from $253.00 to $267.00 and gave the company an "outperform" rating in a report on Wednesday, April 30th. Citigroup raised shares of Laboratory Co. of America from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $250.00 to $300.00 in a research report on Tuesday, March 4th. Jefferies Financial Group lifted their price target on shares of Laboratory Co. of America from $275.00 to $290.00 and gave the company a "buy" rating in a report on Thursday, February 6th. Wall Street Zen lowered Laboratory Co. of America from a "buy" rating to a "hold" rating in a research report on Friday, April 18th. Finally, Redburn Atlantic began coverage on Laboratory Co. of America in a report on Wednesday, April 2nd. They set a "buy" rating and a $276.00 price target on the stock. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Laboratory Co. of America currently has a consensus rating of "Moderate Buy" and an average target price of $272.92.

Laboratory Co. of America Stock Down 0.5%

Shares of NYSE:LH traded down $1.38 during trading on Thursday, reaching $252.99. 247,670 shares of the company traded hands, compared to its average volume of 635,061. The firm has a fifty day simple moving average of $236.48 and a 200 day simple moving average of $238.59. The firm has a market cap of $21.18 billion, a P/E ratio of 28.68, a price-to-earnings-growth ratio of 1.71 and a beta of 0.82. Laboratory Co. of America Holdings has a 1-year low of $192.38 and a 1-year high of $258.59. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.67.

Laboratory Co. of America (NYSE:LH - Get Free Report) last issued its earnings results on Tuesday, April 29th. The medical research company reported $3.84 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.73 by $0.11. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. The company had revenue of $3.35 billion during the quarter, compared to analyst estimates of $3.41 billion. During the same quarter last year, the business posted $3.68 EPS. The company's revenue for the quarter was up 5.3% on a year-over-year basis. Analysts anticipate that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current fiscal year.

Laboratory Co. of America Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 11th. Shareholders of record on Thursday, May 29th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.14%. Laboratory Co. of America's dividend payout ratio is currently 33.29%.

Insider Transactions at Laboratory Co. of America

In other Laboratory Co. of America news, EVP Amy B. Summy sold 758 shares of the company's stock in a transaction that occurred on Friday, March 28th. The stock was sold at an average price of $231.67, for a total transaction of $175,605.86. Following the completion of the transaction, the executive vice president now owns 5,302 shares of the company's stock, valued at $1,228,314.34. This represents a 12.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Adam H. Schechter sold 6,105 shares of the company's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $248.73, for a total transaction of $1,518,496.65. Following the sale, the chief executive officer now directly owns 98,962 shares in the company, valued at $24,614,818.26. This trade represents a 5.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 9,592 shares of company stock worth $2,347,820. 0.84% of the stock is currently owned by company insiders.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.